Bioasis Technologies Inc.
BTI
Rang in Aktien
#39866
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Aktienkurs
$0.00366968
Zuletzt synchronisiert: 2024-07-23
Marktkapitalisierung
$291.42K
Veränderung (1 Tag)
-0.81%
Veränderung (1 Jahr)
1,734.84%
Land
US
Handel Bioasis Technologies Inc. (BTI)
Kategorie
Healthcare
Kursverlauf für Bioasis Technologies Inc. (BTI)
Höchster Schlusskurs: $0.00 am 2026-10-01
Niedrigster Schlusskurs: $0.65 am 2010-12-01
Niedrigster Schlusskurs: $0.65 am 2010-12-01
Kursverlauf der Aktie von Bioasis Technologies Inc. von 2010 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 0.00% |
| 2025 | 100.00% |
| 2024 | -96.84% |
| 2023 | -95.87% |
| 2022 | -63.92% |
| 2021 | -14.37% |
| 2020 | 60.58% |
| 2019 | -48.92% |
| 2018 | -50.78% |
| 2017 | -29.50% |
| 2016 | -3.73% |
| 2015 | -0.24% |
| 2014 | 6.35% |
| 2013 | -55.19% |
| 2012 | 271.36% |
| 2011 | -20.38% |
| 2010 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
